Biologic Drugs in Development

Navigating Biologics Development

September 29, 2023

Biologics formulation comes with a unique set of challenges, which can be overcome through innovative strategies and good partnerships.

Harnessing the Power of Oncolytic Viruses

September 20, 2023

Tumour-infiltrating lymphocyte (TIL) therapies offer a new route to target cancer.

EMA Committee Issues Positive Opinion on Sandoz’ Biosimilar Trastuzumab

September 18, 2023

The EMA’s Committee for Medicinal Products for Human Use has given a positive opinion on Sandoz’ biosimilar trastuzumab for breast and gastric cancer.

Handling New Therapies Moving Through Drug Development at a Rapid Pace

September 13, 2023

Despite the successes that have already been achieved with emerging therapy development and manufacturing, companies are still facing numerous challenges.

Nurix Announces Strategic Collaboration with Seagen

September 13, 2023

Seagen will be responsible for conjugating these degraders to antibodies to make DACs and advancing these DAC drug candidates through preclinical and clinical development and commercialization.

Image Analysis Algorithm for Therapeutic mAb Aggregate Analysis

September 02, 2023

Image analysis algorithms coupled with microscopy techniques can be used to characterize aggregates of therapeutic proteins.

FDA Halts Clinical Trial Enrollment for Gilead’s Magrolimab in AML Studies

August 21, 2023

FDA has halted enrollment in clinical studies for Gilead Sciences’ magrolimab, a biologic treatment in development for acute myeloid leukemia.

Teva Pharmaceuticals and Alvotech Expand Existing Biosimilars Partnership

July 27, 2023

Teva Pharmaceuticals and Alvotech will expand their partnership for the development and commercialization of biosimilar candidates.

EMA Gives Positive Opinion on Two of Janssen’s Bispecific Antibodies

July 27, 2023

Janssen has received a positive opinion from the EMA for two novel bispecific antibodies, TALVEY (talquetamab) and TECVAYLI (teclistamab), which the company is developing to treat blood cancer.

Crossbow Therapeutics Debuts with $80 Million in Series A Financing to Advance Antibody Therapeutics

July 24, 2023

Newly launched Crossbow Therapeutics will work to advance a novel class of antibody therapies for treating cancers.